{"id":"adapalene-bpo-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Peeling"},{"rate":null,"effect":"Irritation"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adapalene is a third-generation retinoid that binds to retinoic acid receptors, promoting keratinocyte differentiation and reducing comedone formation. Benzoyl peroxide acts as an antimicrobial agent against Cutibacterium acnes (formerly Propionibacterium acnes) and generates reactive oxygen species that reduce bacterial colonization. Together, they address multiple pathogenic factors in acne: follicular hyperkeratinization, bacterial proliferation, and inflammation.","oneSentence":"Adapalene-BPO is a combination topical gel that uses a retinoid (adapalene) to normalize skin cell turnover and reduce inflammation, combined with benzoyl peroxide to kill acne-causing bacteria and provide additional anti-inflammatory effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:42.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT05536882","phase":"PHASE3","title":"MC RCT - BPO vs Adapalene","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2022-05-18","conditions":"Molluscum Contagiosum","enrollment":""},{"nctId":"NCT03076320","phase":"PHASE1, PHASE2","title":"Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2017-03-27","conditions":"Acne Vulgaris Superficial Mixed Comedonal and Inflammatory","enrollment":82},{"nctId":"NCT02735421","phase":"PHASE4","title":"Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2016-05-13","conditions":"Acne Vulgaris, Atrophic Acne Scars","enrollment":67},{"nctId":"NCT01951417","phase":"PHASE4","title":"Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-10","conditions":"Acne","enrollment":81},{"nctId":"NCT01209949","phase":"PHASE4","title":"Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-10","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT00687908","phase":"PHASE3","title":"Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-11","conditions":"Acne","enrollment":243},{"nctId":"NCT01188538","phase":"PHASE4","title":"Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-03","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT00688064","phase":"PHASE3","title":"Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2008-08","conditions":"Severe Acne Vulgaris","enrollment":459},{"nctId":"NCT01014689","phase":"PHASE3","title":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":378},{"nctId":"NCT00883233","phase":"PHASE3","title":"Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-04","conditions":"Acne","enrollment":123},{"nctId":"NCT02932267","phase":"PHASE3","title":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-02-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT00441415","phase":"PHASE3","title":"Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Acne Vulgaris","enrollment":272},{"nctId":"NCT00757523","phase":"PHASE4","title":"Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-09-10","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT01910064","phase":"PHASE3","title":"A Long Term Study of GK530G in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2013-05","conditions":"Acne Vulgaris","enrollment":436},{"nctId":"NCT00926367","phase":"PHASE4","title":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT01149330","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma Brasil Ltda.","startDate":"2010-07","conditions":"Acne Vulgaris","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Adapalene-BPO Gel","genericName":"Adapalene-BPO Gel","companyName":"Galderma Brasil Ltda.","companyId":"galderma-brasil-ltda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adapalene-BPO is a combination topical gel that uses a retinoid (adapalene) to normalize skin cell turnover and reduce inflammation, combined with benzoyl peroxide to kill acne-causing bacteria and provide additional anti-inflammatory effects. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}